ClinicalTrials.gg
CompletedNCT00773630Updated Sep 9, 2011

A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions

A Phase 1 interventional study of Cilostazol in Intermittent Claudication, sponsored by Otsuka Frankfurt Research Institute GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-09-09.

Sponsored by Otsuka Frankfurt Research Institute GmbH (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Intermittent Claudication with a site in Germany — 1 open to participants now, 2 under way, none of them phase 3. Intermittent Claudication · Germany.

Enrollment
17th of 24
44 · median 82
Started
2008
the only one that year
Phase 1
Only one
of the 30
Registered
3rd of 30
by date

Among the 30 studies in Intermittent Claudication with a site in Germany, this one is the 17th largest by enrollment of the 24 interventional ones that give a count, is the only one that started in 2008, is the only one in phase 1, and was the 3rd registered.

Intermittent Claudication

309 studies on the registry are indexed under Intermittent Claudication; 46 are open to participants now.

Browse Intermittent Claudication studies →

Open to participants now

1 of the 30 studies in Intermittent Claudication with a site in Germany is open now. Recruiting first, the newest first:

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 33 Intermittent Claudication studies recruiting now, 21 (64%) set no upper age limit and none (0%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Intermittent Claudication with a site in Germany, or all of them as a file.
02

Study summary

The primary objective of this trial is to test whether Pletal ODT administered without water can be considered bioequivalent to Pletal administered with 200 ml water (both treatments being administered after fasting and at least 30 minutes prior to receiving a light breakfast) based on the standard pharmacokinetic variables.

The secondary objective is to assess the effect of water and the effect of food on the administration of Pletal ODT based on standard pharmacokinetic variables.

03

Conditions studied

  • Intermittent Claudication
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. healthy male and female subjects of Caucasian race
  2. able to read, to write and to fully understand German language
  3. having given voluntary written before first invasive screening examination procedure
  4. aged 18 to 45 years, inclusive
  5. of 18 - 28 kg/m2
  6. good health as determined by medical history, physical examination, vital signs, (ECG, serum/urine biochemistry and hematology)

Exclusion criteria

Exclusion Criteria:

  1. allergy (except for untreated, asymptomatic, seasonal allergies at time of dosing) drug
  2. known hypersensitivity to one of the IMP substances
  3. severe digestive disorder or surgery of the digestive tract (except for appen¬dectomy)
  4. clinically relevant renal disorders (albuminuria, chronic infections)
  5. clinically relevant hepatic disorders
  6. clinically relevant respiratory disorders
  7. clinically relevant cardiovascular disorders, especially any history of ventricular tachycardia, ventricular fibrillation or multifocal ventricular ectopics, or a history of additional risk factors for torsades de pointes (TdP) (e.g. heart failure, hypokalemia, congenital long -syndrome)
  8. diabetes mellitus and thyroid dysfunction or other endocrine disorders
  9. substance abuse or addiction (alcohol, illicit drugs) in the past 3 years
  10. neurologic or psychiatric illness
  11. known predisposition to bleeding (e.g. active peptic ulceration, recent (within 6 month) haemorrhagic stroke, surgery within the previous three months, proliferative diabetic retinopathy, poorly controlled hypertension)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Active comparator
    A

    Intake of Pletal 100 mg tablets dose together with 200 ml water

    Drug: Cilostazol

  • Experimental
    B

    Intake of Pletal 100 mg ODT dose without water

    Drug: Cilostazol

  • Experimental
    C

    Intake of Pletal 100 mg ODT dose together with 200 ml water

    Drug: Cilostazol

  • Active comparator
    D

    Intake of Pletal 100 mg ODT dose without water

    Drug: Cilostazol

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the curve, maximal concentration (Cmax)

    Time frame: 1-2 months

Secondary outcomes

  1. Time of maximum (tmax), Vss/f, CL/f)

    Time frame: 1-2 months

07

Study locations

1 site
  • AAIPharma Deutschland GmbH & Co. KG
    Neu-Ulm, 89231, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2008
First posted
Oct 16, 2008
Start
Dec 2008
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Last update
Sep 9, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00773630
Responsible party
Sponsor
First posted
Oct 16, 2008
Start date
Dec 2008
Primary completion
Mar 2009
Completion
Mar 2009
Last update
Sep 9, 2011

Study contacts

Margarete Mueller, Dr.
principal investigator · AAIPharma Deutschland GmbH & Co. KG

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilostazol

Start the discussion